Home LiteratureArticle Details
PMID: 6795122 Published · ppublish English Clinical Trial Controlled Clinical Trial Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Group C Neisseria meningitidis variant polysaccharide vaccines in children.

Infection and immunity ·Vol. 34 ·No. 1 ·1981-10-00 ·Pages 144-6

Steinhoff MC, Lewin EB, Gotschlich EC, Robbins JB

Abstract

The currently United States-licensed group C Neisseria meningitidis vaccine, composed of the O-acetyl-positive capsular polysaccharide, is poorly immunogenic and does not afford protection from disease to infants and young children. Group C N. meningitidis O-acetyl-negative polysaccharide vaccine induces higher titers in adults than does the O-acetyl-positive vaccine. We compared the immunogenicity of these vaccines in 2-year-old children. Reactions were minimal and did not differ between the two vaccines. The postvaccination geometric mean titer was twofold greater in the O-acetyl-negative group (1.58 versus 0.73 micrograms of antibody per ml). The rates of decline in titer were similar in both groups. Further study regarding immunogenicity of and the anamnestic response to the O-acetyl-negative vaccine is warranted in the age group (less than 18 months) at highest risk for invasive meningococcal disease.

MeSH Terms
Antibodies, Bacterial/analysis Bacterial Vaccines/immunology Child, Preschool Humans Nasopharynx/microbiology Neisseria meningitidis/immunology,isolation & purification Polysaccharides, Bacterial/immunology Rectum/microbiology Time Factors Vaccination
Chemicals
Antibodies, Bacterial Bacterial Vaccines Polysaccharides, Bacterial
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Steinhoff M C
Lewin E B
Gotschlich E C
Robbins J B
References (9)
9 references, click to expand
  1. Human immunity to the meningococcus. I. The role of humoral antibodies.
    J Exp Med. 1969 Jun 1;129(6):1307-26 PMID: 4977280
  2. Quantitative determination of the human immune response to immunization with meningococcal vaccines.
    J Clin Invest. 1972 Jan;51(1):89-96 PMID: 4621363
  3. Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70.
    Bull World Health Organ. 1971;45(3):279-82 PMID: 5316907
  4. Serologic response to serogroup C meningococcal vaccine in Brazilian preschool children.
    Rev Inst Med Trop Sao Paulo. 1974 May-Jun;16(3):149-53 PMID: 4421873
  5. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children.
    J Infect Dis. 1979 Nov;140(5):690-7 PMID: 118997
  6. Immune Response of human infants of polysaccharide vaccines of group A and C Neisseria meningitidis.
    J Infect Dis. 1977 Aug;136 Suppl:S31-5 PMID: 408431
  7. Strucutres of the capsular polysaccharides of Neisseria meningitidis as determined by 13C-nuclear magnetic resonance spectroscopy.
    J Infect Dis. 1977 Aug;136 Suppl:S78-83 PMID: 408435
  8. Comparative immunogenicity of vaccines prepared from capsular polysaccharides of group C Neisseria meningitidis O-acetyl-positive and O-acetyl-negative variants and Escherichia coli K92 in adult volunteers.
    J Infect Dis. 1979 Jan;139(1):52-9 PMID: 108338
  9. Standardization and control of meningococcal vaccines, group A and group C polysaccharides.
    J Biol Stand. 1977;5(3):197-215 PMID: 408354
Article Info
Journal
Infection and immunity
Abbr.
Infect Immun
ISSN
0019-9567
Published
1981-10-00
Pages
144-6
Language
English
Region
United States
NLM ID
0246127
PMCID
PMC350834
Subset
IM
Grants
NIAID NIH HHS · N01-AI-22502 · United States
NIAID NIH HHS · N01-AI-22503 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]